HIGH-POTENCY SARS CORONAVIRUS 2 ANTIGEN AND VACCINE COMPOSITION COMPRISING SAME

Abstract

Provided are a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof, a vaccine composition comprising the recombinant antigen, a gene construct comprising a polynucleotide encoding the recombinant antigen, a recombinant vector comprising the gene construct, a method for producing the SARS-CoV-2 recombinant antigen, and a kit for preventing or treating SARS-CoV-2 infection comprising the vaccine composition and users' instruction thereof, wherein the antigen exhibited higher immunogenicity against SARS-CoV-2 the neutralizing antibody was better formed in actual animal experiments, excellent protective immunity was induced, and toxicity did not appear in the toxicity test.

Claims

1.-11. (canceled)

12. A recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof.

13. The recombinant antigen according to claim 12, wherein the SARS-CoV-2 antigen comprises a receptor binding domain (RBD) or fragment thereof.

14. The recombinant antigen according to claim 12, wherein the SARS-CoV-2 antigen comprises SEQ ID NO: 24 or a fragment thereof.

15. The recombinant antigen according to claim 12, wherein the recombinant antigen comprises at least one selected from the group consisting of SEQ ID NOs: 26 to 47.

16. A gene construct comprising a polynucleotide encoding the recombinant antigen according to claim 12.

17. A recombinant vector comprising the gene construct according to claim 16.

18. A vaccine composition comprising the recombinant antigen according to claim 12.

19. The vaccine composition according to claim 18, wherein the vaccine composition has a SARS-CoV-2 specific neutralizing ability.

20. The vaccine composition according to claim 18, wherein the vaccine composition is for preventing or treating SARS-CoV-2 infection.

21. A method for producing a SARS-CoV-2 recombinant antigen comprising: a step of identifying the gene or amino acid sequence of SARS-CoV-2 antigen or fragment thereof; a step of binding of a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24; a step of preparing a recombinant antigen in which an antigen and a cell membrane penetrating domain are fused in a system for overexpressing an immunogen in human cells; and a step of purifying the recombinant antigen.

22. A kit for preventing or treating SARS-CoV-2 infection comprising a vaccine composition and instructions for use, the vaccine composition comprising a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof.

23. The recombinant antigen according to claim 12, wherein the SARS-CoV-2 antigen comprises at least one selected from the group consisting of inactivated whole SARS-CoV-2 antigen, spike protein, nucleoprotein, envelope, 51 domain, S2 domain, RBD, N-terminus, C-terminus and fragments thereof.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] FIG. 1 shows a comparison result of the amino acid sequence of SARS-CoV-2 receptor binding domain and SARS coronavirus receptor binding domain of Example 1 according to an embodiment of the present invention (FIG. 1a) and SARS-CoV-2 signal peptide sequence analysis result (FIG. 1b). And, the schematic diagram (FIG. 1c) of the recombinant SARS-CoV-2 antigen structure fused with the cell membrane penetrating domain (LRRC24P) derived from the human LRRC24 protein is shown.

[0017] FIG. 2 shows the results of verifying the purified antigen through coomassie blue staining (A) and Western blot analysis using an antibody specific for SARS-CoV-2 spike protein (B), after the two types of SARS-CoV-2 antigens of Example 1 according to an embodiment of the present invention were purified in large quantities using animal cells,

[0018] FIG. 3 shows a schematic diagram (A) showing the process of obtaining serum for evaluation of neutralizing antibody production ability by inoculating C57/BL6 mice with the recombinant SARS-CoV-2 antigen of Example 2 according to an embodiment of the present invention, and the result (B, C) of confirming the neutralizing antibody titer of SARS-CoV-2 generated in the serum through Focus reduction neutralization test (FRNT)

[0019] FIG. 4 shows a schematic diagram (A) showing the process of inoculating C57/BL6 mice with the recombinant SARS-CoV-2 antigen of Example 2 according to an embodiment of the present invention, and obtaining serum for evaluation of antigen-specific immunoglobulin G production ability, and the result (B) of confirming the production of SARS-CoV-2 RBD-specific immunoglobulin G in serum through ELISA assay.

DETAILED DESCRIPTION OF THE INVENTION

[0020] Hereinafter, preferred embodiments of the present invention will be described in detail. In addition, in the following description, many specific details such as specific components are shown, which are provided to help a more general understanding of the present invention, and it will be apparent to those skilled in the art that the present invention may be practiced without these specific details. And, in describing the present invention, if it is determined that a detailed description of a related known function or configuration may unnecessarily obscure the gist of the present invention, the detailed description thereof will be omitted.

[0021] The present invention provides a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof;

[0022] The present invention is obtained in the same way as domestic application No. 10-2019-0144779, a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 protein according to an embodiment of the present invention.

[0023] The SARS-CoV-2 antigen according to an embodiment of the present invention refers to all antigenic components included in SARS-CoV-2, preferably the recombinant antigen comprising any one or more selected from the group consisting of inactivated whole SARS-CoV-2 antigen, spike protein, nucleoprotein, envelope, S1 domain, S2 domain, receptor binding domain (RBD), N terminus, C terminus and fragments thereof, and more preferably, a receptor binding domain (RBD), and still more preferably, SEQ ID NO: 24 or a fragment thereof, but is not limited thereto.

[0024] The recombinant antigen according to one embodiment of the present invention comprises the number of all cases combined a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof, and preferably a recombinant antigen comprising at least one selected from the group consisting of SEQ ID NOs: 26 to 47, but is not limited thereto.

[0025] Also the present invention provides gene construct comprising a polynucleotide encoding a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof;

[0026] In the gene construct of the present invention, the nucleotide sequence is preferably present in a suitable expression construct. In the expression construct, the nucleotide sequence is preferably operably linked to a promoter.

[0027] As used herein, the term “operably linked” refers to a functional linkage between a nucleic acid expression control sequence (e.g., an array of promoters, signal sequences, or transcriptional regulator binding sites) and another nucleic acid sequence, whereby the control sequence regulates the transcription and/or translation of the other nucleic acid sequence.

[0028] As another example, the present invention provides a recombinant vector comprising a gene construct comprising a polynucleotide encoding a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof;

[0029] The present invention provides a vaccine composition comprising recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof;

[0030] In one embodiment of the present invention, the vaccine composition has a specific neutralizing ability of SARS-CoV-2 and is for preventing or treating SARS-CoV-2 infection, but is not limited thereto.

[0031] The vaccine composition of the present invention includes a pharmaceutically acceptable carrier in addition to the active ingredient. A pharmaceutically acceptable carrier included in the vaccine composition of the present invention is commonly used in formulation, and comprises lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydride hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like, but is not limited thereto. The vaccine composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and agents are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0032] In addition, the vaccine composition of the present invention is formulated in a unit dosage form by using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains or can be prepared by incorporation into a multi-dose container. Vaccine compositions may be formulated using methods known in the art to permit rapid, or sustained or delayed release of the active ingredient upon administration to a mammal. Formulations include powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, and sterile powder forms, but is not limited thereto.

[0033] A suitable dosage of the vaccine composition of the present invention may be prescribed variously depending on factors such as formulation method, administration mode, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity of the patient. Otherwise, the dosage of the pharmaceutical composition of the present invention is preferably 0.001-1000 mg/kg (body weight) per day, but is not limited thereto.

[0034] The vaccine composition can be injected into humans or non-human animals to increase the antibody production rate against the antigen, and the injection may be performed by any one method selected from the group consisting of subcutaneous injection, intramuscular injection, intraperitoneal injection, nasal administration, oral administration, transdermal administration and oral administration.

[0035] The vaccine composition according to an embodiment of the present invention may additionally include an adjuvant composition, an immunostimulator or an adjuvant to increase efficacy. Vaccine adjuvants are largely classified into three types according to their mechanism of action: antigen carriers, immune enhancers, and those that stimulate immune responses and act as a matrix for antigens. Effective use of vaccine adjuvants can have various effects, such as (1) increasing the immunogenicity of recombinant antigens, (2) reducing antigen doses or reduce the number of immunizations, and (3) improving immunogenicity in infants and the elderly with weakened immunity. As the vaccine adjuvant, an adjuvant component known in the art may be used, preferably aluminum salt, MF59, AS03, AS04, etc. may be used alone or in combination, and more preferably, alum may be used, but is not limited thereto.

[0036] As another example, the present invention provides a method for producing a SARS-CoV-2 recombinant antigen comprising:

[0037] the step of identifying the gene or amino acid sequence of the SARS-CoV-2 antigen or fragment thereof;

[0038] the step of binding of a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24

[0039] the step of preparing a recombinant antigen in which an antigen and a cell membrane penetrating domain are fused in a system for overexpressing an immunogen in human cells;

[0040] the step of purifying the recombinant antigen;

[0041] The present invention also provides a kit for preventing or treating SARS-CoV-2 infection comprising a vaccine composition and instructions for use comprising a recombinant antigen comprising a cell membrane permeation domain comprising a polypeptide of any one of SEQ ID NOs: 1 to 22 derived from human LRRC24 and a SARS-CoV-2 antigen or a fragment thereof;

[0042] Advantages and features of the present invention, and methods of achieving them, will become apparent with reference to the embodiments described below in detail. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in various different forms, and only the present embodiments are provided so that the disclosure of the present invention is complete, and to completely inform those of ordinary skill in the art to which the present invention belongs, the scope of the invention, and the invention is only defined by the scope of the claims.

<Example 1> Production and Purification of Recombinant Antigen of SARS-CoV-2 Receptor Binding Domain (RBD) Fused with a Cell Membrane Permeation Domain Derived from Human LRRC24 (Leucine Rich Repeat Containing 24) Protein

[0043] A nucleotide sequence expressing the Spike protein was obtained using the published SARS-CoV-2 gene sequence (GenBank ID: MN908974.3). The corresponding amino acid sequence was compared with the previously known SARS-CoV-2 receptor binding domain for homology using the amino acid sequence align tool on the SnapGene program (FIG. 1a). Through this, the amino acid sequence of the novel coronavirus receptor binding domain was obtained. Receptor binding domain corresponds to amino acids 319 to 541 of the novel coronavirus spike protein. In order to express the corresponding gene sequence in eukaryotic cells, after codon optimization was performed, the gene synthesis was performed by IDT company. In addition, since releasing the protein out of the cell helps in protein expression and purification, a signal peptide responsible for the release of the novel coronavirus spike protein was revealed (FIG. 1b). Through an analysis program called SignalP, it was confirmed that 1 to 16 amino acids of the spike protein could play this role, and this was used for immunogen expression.

[0044] A recombinant antigen of the SARS-CoV-2 receptor binding domain (RBD) fused to cell membrane penetrating domain (LRRC24P) derived from the human LRRC24 protein was constructed using a system that overexpresses an immunogen in human cells (FIG. 1c). For efficient protein purification, an immunogen (SARS-CoV-2 RBD) in which six histidine amino acid tags were fused to the C-terminus of SARS-CoV-2 RBD was prepared. To study the vaccine efficacy improvement function of cell membrane penetrating domain (LRRC24P) derived from the human LRRC24 protein, a fused SARS-CoV-2 RBD-LRRC24P antigen was prepared. Both antigens had a His-tag, so they were purified using a Ni-NTA agarose column (QIAGEN). The bulk purified recombinant antigen was confirmed by Coomassie blue staining (FIG. 2A) and Western blot analysis (FIG. 2B). A high-purity immunogen was produced and used to evaluate vaccine efficacy.

<Example 2> Immunization and Determination of Neutralizing Antibody Titers in Wild-Type Mice of Recombinant Antigen of SARS-CoV-2 Receptor Binding Domain (RBD) Fused with a Cell Membrane Permeation Domain Derived from Human LRRC24 Protein

[0045] Recombinant antigens of SARS-CoV-2 receptor binding domain (RBD) fused with a cell membrane permeation domain derived from human LRRC24 obtained in Example 1 were immunized according to the study schedule presented in FIG. 3A. Recombinant immunogen was inoculated using 10 micrograms per mouse. Each antigen was tested using 6 mice per group. As an adjuvant, Alum from Thermo Fisher Scientific was used. The first immunization (priming) was performed on day 0 by injecting the mouse intramuscularly with the immunogen. The immunization was repeated on the 14th (2nd) and 28th (3rd) days for immune boosting. After three vaccinations, mouse serum was obtained according to the schedule shown in FIG. 3A and neutralizing antibody titers were measured. To measure the neutralizing antibody titer against SARS-CoV-2, mouse serum was diluted 40-fold in minimal essential medium, and reacted with SARS-CoV-2 at 37° C. The viral serum mixture was added to the monolayer cells cultured in 96-well flasks and then incubated in a 5% carbon dioxide incubator at 37° C. for 8 hours. In the control group without neutralizing antibody, the specific antibody reaction effect by SARS-CoV-2 occurs well. In the presence of a neutralizing antibody, the effect of the antibody reaction specific to SARS-CoV-2 does not occur well. This was quantitatively measured through a focus reduction neutralization test (FRNT) assay, and the level of neutralizing antibody was quantified by calculating a dilution factor representing 50% of the intracellular SARS-CoV-2 specific antibody level.

[0046] As the result shown in FIG. 4, it was confirmed that the neutralizing antibody produced in mice immunized with the recombinant antigen of the SARS-CoV-2 receptor binding domain (RBD) fused to cell membrane penetrating domain (LRRC24P) derived from the human LRRC24 protein produced immunoglobulin G specific for the SARS-CoV-2 Receptor binding domain (RBD). (FIGS. 4A and 4B)